Equities

Vaxart Inc

Vaxart Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.8344
  • Today's Change-0.072 / -7.91%
  • Shares traded2.01m
  • 1 Year change+12.54%
  • Beta0.6721
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Vaxart Inc grew revenues 6,796.26% from 107.00k to 7.38m while net income improved from a loss of 107.76m to a smaller loss of 82.47m.
Gross margin--
Net profit margin-543.21%
Operating margin-538.83%
Return on assets-64.01%
Return on equity-91.66%
Return on investment-73.18%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Vaxart Inc fell by 11.26m. However, Cash Flow from Investing totalled 43.95m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 70.45m for operations while cash generated from financing totalled 15.24m.
Cash flow per share-0.4132
Price/Cash flow per share--
Book value per share0.3518
Tangible book value per share0.3148
More ▼

Balance sheet in USDView more

Vaxart Inc appears to have a strong balance sheet with enough cash in the capital structure to pay down 100% of the liabilities.
Current ratio4.54
Quick ratio--
Total debt/total equity0.0535
Total debt/total capital0.0507
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.